“Efficacy and safety study of “KSM-66® ashwagandha” in Swiss Albino mice”
This study was performed to assess the efficacy of KSM-66® ashwagandha, when given for 28
consecutive days to Swiss Albino Mice by oral route.
|No.of mice taken for the study :
||72 (Male 36 and Female 36)
|Duration of study :
- KSM-66® ashwagandha administered group showed statistically significant increase in the Neutrophil counts compared to control and cyclophosphamide group.
- KSM-66® exhibited significant protection from neutropenia at much lower dosages as compared to other extract (hydro-alcoholic) of ashwagandha
- KSM-66® prevented cyclophosphamide induced neutropenia in mice, thereby acting as an immunomodulatory agent, which may be used during chemotherapy and radiotherapy.
- There was a significant indication of spleen lymphocyte proliferation activity in mice during this study.
- Protective effect of KSM-66® on drug induced neutropenia, strongly suggests that this drug may be used as a potent immunomodulator.
- It was also found that KSM-66® was clinically well tolerated up to 1300 mg/kg bodyweight when administered orally to Swiss albino mice for 14 days
CPA = Cyclophosphamide